A study published in the journal “Progress in Cardiovascular Diseases” refutes the frequently repeated claims that a comprehensive salt reduction would not produce any overall health benefits, or would even increase diseases and shorten the life-span.
“Cardiovascular disease remains our country’s biggest killer,” said Minister Clement. “Canada’s new government is following through on our promise to develop a heart health strategy. The strategy developed will ensure crucial information on prevention and treatment is available quickly and effectively to all provinces and territories. A new Heart Health Strategy will save lives.”
Pfizer Inc provided an update on the preliminary results of its torcetrapib/atorvastatin clinical trials in connection with the release of an American Heart Association abstract of a Phase 3 study in patients with heterozygous familial hypercholesterolemia (HeFH) that shows the drug significantly raising ‘good’ (HDL) cholesterol (56 percent) and additionally lowering ‘bad’ (LDL) cholesterol (27 percent) versus patients taking atorvastatin alone.
The Parliamentary Secretary to the Minister for Health and Ageing, Christopher Pyne, announced today the establishment of a National Collaboration on Trans Fats that will propose initiatives aimed at reducing the amount of trans fatty acids in food sold in Australia. Mr Pyne said that the National Heart Foundation of Australia, the Dietitians Association of Australia, the Australian Food and Grocery Council and Food Standards Australia New Zealand (FSANZ) would lead the initiative.
Ottawa will invest $8.4-million over the next two years to develop a new heart health strategy, the Health Minister says. The money will initially be used to determine the extent of cardiovascular disease in Canada, and hypertension in particular, and then to shape a plan of attack, Tony Clement said.
Royal Philips (NYSE: PHG, AEX: PHI) will showcase innovative cardiac solutions designed to streamline workflow and facilitate advanced information management at Cardiovascular Research Foundation?s (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.Shown for the first time ever in the U.S., the pre-release of the Philips Xcelera 2.1 Cardiovascular Information Solution is one of the key components to Philips integrated catheterization (cath) lab, which includes physiomonitoring, reporting and cardiovascular X-ray technologies to improve patient care and lab management.
According to a review of clinical trials, benefits of pioglitazone for type 2 diabetes is unclear. Marketed by Takeda Pharmaceuticals and Eli Lilly & Co. as Actos, pioglitazone belongs to a class of drugs called thiazolidinediones that work by increasing the body’s sensitivity to insulin, to better control patients’ blood sugar. It is used alone or in combination with other drugs if diabetes can’t be controlled by diet and exercise.
The link between short sleep duration and obesity: We should recommend more sleep to prevent obesity. Soaring levels of obesity might be linked to children sleeping fewer hours at night than they used to, claims a researcher in the Archives of Disease in Childhood.
Case Western Reserve University’s Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a “first in class” drug that targets a specific DNA repair pathway.
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for bifeprunox, an investigational atypical antipsychotic for the treatment of schizophrenia.